Follow us:

For Investors

 

Highlights:

  • InspireMD addresses a growing, $1.8B market
  • Target market has limited competition
  • Aging population and desire for less invasive therapies create favorable growth demographics

 

InspireMD to Report Financial Results for the Second Quarter Ended June 30, 2014 on Wednesday, July 23rd at 4:30pm (EST)

 

 

 

Summary:

InspireMD Ltd. is a high growth medical device company focusing on the development and commercialization of its proprietary stent platform technology: MGuard™.

 

InspireMD has created a unique, patent-pending mesh net technology that wraps a stent, providing embolic protection (preventing Major Adverse Cardiac Events (MACE) by filtering debris) and reducing vessel injury by spreading strut pressure. MGuard™ is delivered with no change to the current procedure and is well-accepted by physicians. MGuard™ has been implanted in thousands of patients, and in clinical trials it has shown a more than 50% reduction in MACE compared with traditional bare metal stents.

ASTUDIO | Design & Development